Condition category
Urological and Genital Diseases
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Donated kidneys are extremely precious, and we want to make sure that they are transferred from the donor to the recipient in the best possible condition. People donating kidneys can be treated in two different ways – sometimes they are admitted into hospital overnight and given fluid through a drip in their arm, and sometimes they come into hospital in the morning of the surgery. So far, neither of these approaches has been shown to be better than the other. However, there now exists a new blood test which looks at the levels of a protein called N-GAL in the blood. It is much more sensitive at measuring how well the kidneys are working than older tests. The purpose of the study is to compare these two approaches. This may help determine whether one of these approaches enables the kidney to be transplanted in a better condition, or whether there is no difference between them. To do this, the new blood test will be used. Also, during the operation, as well as normal monitoring, an extra monitoring device will be used. It will be used to monitor the donor’s heart and the way in which blood is pumped around the body, to see whether this is affected by the different approaches.

Who can participate?
Anyone who is donating a kidney at the Western Infirmary (or the South Glasgow University Hospital, when the department moves there) while this trial is going on.

What does the study involve?
As a kidney donor you will be admitted to hospital the night before the operation as normal, and randomly allocated to one of two groups. One group will be given fluids through a drip in the arm, whereas the other group will not. Both groups will have access to water and be able to drink freely overnight. Just before and during the operation, in addition to the standard monitoring, four small electrode stickers will be applied to your chest and neck to assess blood flow and a probe placed on your fingers to measure your blood pressure continuously. These additional monitors will be applied in the anaesthetic room immediately before your surgery. The information gained from these measurements will not affect your care during the operation, which will be undertaken in the standard fashion. Several blood samples will be collected for the few days after the operation. The blood will be drawn at the same time as the routine samples that would normally be taken as part of your care. This means that you shouldn’t be subject to extra needle punctures of your skin. During the operation, two blood samples will be taken from you, but these will be taken while you are under the anaesthetic so you will not feel them. Altogether, maximum of 12 blood samples will be collected. These will each be a maximum of 20 ml (about one tablespoon). These samples will not have your name or personal details recorded on them. They will be transferred to a laboratory at Glasgow University, analysed and stored there in a sample bank. The samples may subsequently be re-analysed in future approved research. We will record information about your progress for one year after the transplant. This information will be stored in an anonymised way – it will not contain your name or personal details.

What are the possible benefits and risks of participating?
As the two groups of patients are being treated slightly differently, it might be that one of the groups has a slightly different outcome. The results of this study may eventually help improve the outcomes for kidney transplantation in the future. No significant risks or disadvantages are anticipated. Although during the operation the donor will be attached to an extra monitor, the data generated by this monitor will have no impact on your care. You will need to provide blood samples as detailed above.

Where is the study run from?
The study will be run from the Western Infirmary, Glasgow, until the department is transferred to the new South Glasgow University Hospital, where the study will continue to run.

When is the study starting and how long is it expected to run for?
January 2015 to January 2017

Who is funding the study?
Transplant and Renal Failure Surgery Endowment Fund (UK)

Who is the main contact?
Marc Clancy

Trial website

Contact information



Primary contact

Mr Marc Clancy


Contact details

Renal Transplant Unit
Western Infirmary
Dumbarton Road
G11 6NT
United Kingdom
+44 (0)141 211 2816

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

A Comparison of the effects of Oral vs INtravenous hydration on Subclinical acute kidney injury: a randomised controlled trial



Study hypothesis

The use of preoperative intravenous fluids will result in a measurable improvement in intraoperative haemodynamics and a decrease in donor subclinical acute kidney injury, as measured by N-GAL.

Ethics approval

West of Scotland Research Ethics Committee 3, West of Scotland Research Ethics Service, 27/01/2015, ref: 14/WS/1160.

Study design

Prospective single-centre single-blinded randomized controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use contact details to request a participant information sheet


Live kidney donors


Patients will be randomly assigned to one of two groups using a computer-generated randomisation schedule.

Preoperative Intravenous Fluid Group
The evening prior to surgery (day -1), between midnight and 8 am, patients in this group will receive three litres of crystalloid solution, IV, in addition to unrestricted oral fluid in line with the pre-operative fasting guidelines produced by the Association of Anaesthetists of Great Britain and Ireland.

No Preoperative Intravenous Fluid Group
Patients in this group will also be admitted on the evening prior to surgery (day -1) but will not be given intravenous fluids. They will therefore only receive unrestricted oral fluids in accordance with The Association of Anaesthetists of Great Britain and Ireland fasting guidelines.

Intervention type



Drug names

Primary outcome measure

Day +1 acute kidney injury (as measured by N-GAL)

Secondary outcome measures

1. Day 1 change in donor N-GAL from baseline
2. Donor renal function (serum creatinine and eGFR) day 1-4, week 6 and 1 year, as is standard procedure
3. Donor BNP (Day -1, Day 0, Day 1)
4. Recipient change in N-GAL from baseline
5. Recipient serum creatinine and eGFR at 6 weeks and 1 year
6. Delayed graft function (DGF) – defined as use of dialysis in the first week postoperatively
7. 1-year graft and patient survival in recipient
8. Intraoperative haemodynamics (including blood pressure, heart rate, stroke volume, cardiac index and systemic vascular resistance index) and response to fluid challenge
9. N-GAL levels in blood obtained from renal vein during retrieval and implantation surgery
10. Perioperative mortality
11. Perioperative fluid balance
12. Perioperative complications (including cardiorespiratory complications, time to first bowel motion, infective complications, length of hospital stay, readmission)
13. Donor sleep quality

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Adult patients aged >18 years of age undergoing live donor hand-assisted laparoscopic nephrectomy eligible to participate
2. Consent to participate given
3. English-speaking or appropriate translation facilities to allow for consent to be valid
4. Living donor transplant in Western Infirmary, Glasgow
5. Transplant taking place between dates of the trial

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Patients undergoing open nephrectomy
2. Patients unable/unwilling to consent

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Western Infirmary
Dumbarton Road
G11 6NT
United Kingdom

Trial participating centre

South Glasgow University Hospital
G51 4SX
United Kingdom

Sponsor information


NHS Greater Glasgow and Clyde

Sponsor details

c/o Dr Maureen Travers
Research Coordinator
R&D Management Office
Tennent Institute
38 Church Street
G11 6NT
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type

Hospital/treatment centre

Funder name

Transplant and Renal Failure Surgery Endowment Fund

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

To be confirmed at a later date

Intention to publish date

Participant level data

Not expected to be available

Basic results (scientific)

Publication list

2017 protocol in:

Publication citations

Additional files

Editorial Notes

23/01/2017: Publication reference added.